• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse

    Gabrielle Lakusta
    Feb. 13, 2018 09:04AM PST
    Pharmaceutical Investing

    Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the results of its recent Type C meeting with the U.S. Food and Drug Administration. As quoted in the press release: “We remain on track to resubmit our NDA for …

    Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the results of its recent Type C meeting with the U.S. Food and Drug Administration.

    As quoted in the press release:

    “We remain on track to resubmit our NDA for Firdapse in the first quarter of this year,” stated Patrick J. McEnany, President and CEO of Catalyst Pharmaceuticals. “Based on our discussions with the FDA, we believe that we have a clear regulatory pathway forward, and we will continue to work collaboratively with the FDA as we seek to bring FDA approved therapies forward for the treatment of LEMS and CMS.”

    Click here to read the full press release.

    catalyst pharmaceuticalspharmaceutical investingfood and drug administration
    The Conversation (0)
    Go Deeper
    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks in 2025

    Canada maple leaves on left and pharmaceutical pills in red and blue on right.

    5 Best-performing Canadian Pharma Stocks (Updated January 2025)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

     
    IVX:AU

    Cardiol Therapeutics

     
    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—